AudioBoom | https://audioboom.com/posts/8226309-jeremy-skillington-of-poolbeg-pharma-early-data-read-out-for-polb-001-indicates-a-successful-lps

If you find this podcast useful please give it a rating and review on iTunes by clicking here

POOLBEG PHARMA POLB
Jeremy Skillington, CEO of Poolbeg Pharma  discusses the positive initial data analysis in POLB 001 LPS Challenge Trial and says a full data read-out is expected in Q2 2023 following a final quality check of the unblinded data.

Highlights

- POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo
- A clear dose-response relationship was demonstrated
- Well tolerated across all doses and no serious adverse events or volunteer withdrawals were reported
- Full data read-out expected in Q2 2023 following a final quality check of the unblinded data

To read the full RNS click here